Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + velpatasvir + ribavirin + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This drug combination is a quadruple therapy regimen consisting of sofosbuvir, velpatasvir, ribavirin, and peginterferon alfa-2b, specifically investigated for the re-treatment of chronic hepatitis C virus (HCV) infection in patients who have failed or relapsed after prior direct-acting antiviral (DAA) therapy. Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-dependent RNA polymerase, while velpatasvir is an NS5A inhibitor that disrupts viral replication and assembly. Ribavirin is a guanosine analog with broad antiviral activity, and peginterferon alfa-2b is a pegylated cytokine that stimulates the host immune response via the interferon-alpha/beta receptor. This intensive regimen aims to overcome resistance in difficult-to-treat populations, such as those with genotype 3 or cirrhosis, by combining multiple mechanisms of action.
- Other names
- SOF/VEL + RBV + PEG-IFN
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR (Immune system modulation via type I interferon receptor)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on sofosbuvir + velpatasvir + ribavirin + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + velpatasvir + ribavirin + peginterferon alfa-2b.